Insight Molecular Diagnostics (IMDX) Income from Non-Controlling Interests (2017)
Insight Molecular Diagnostics (IMDX) posted Income from Non-Controlling Interests of $142000.0 for Q2 2017, down 8.39% sequentially from $155000.0 in Q1 2017.
Insight Molecular Diagnostics (IMDX) Income from Non-Controlling Interests (2017) Analysis & Trends
Insight Molecular Diagnostics has reported Income from Non-Controlling Interests for 1 years, with the latest figure at $142000.0 in Q2 2017.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $142000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was $297000.0 (changed N/A YoY) and the FY2017 annual result came in at $293000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests fell to $142000.0 in Q2 2017 per IMDX's latest filing, from $155000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $155000.0 in Q1 2017 and troughed at $142000.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.77 Bn | 209.71 Bn | 8.34 Bn | 5.00 Mn |
| 2 | Danaher | 139.78 Bn | 135.43 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.04 Bn | 45.85 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.68 Bn | 37.88 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.34 Bn | 37.26 Bn | 1.44 Bn | 2.00 Mn |
| 6 | Natera | 38.75 Bn | 37.65 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.90 Bn | 28.73 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.58 Bn | 28.53 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.18 Bn | 25.55 Bn | 1.03 Bn | 14.00 Mn |
| 10 | Insight Molecular Diagnostics | 174.32 Mn | 145.39 Mn | 15,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 142,000.00 |
| Mar 31, 2017 | 155,000.00 |